Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. Unlike most agents in its class, it is primarily excreted via the biliary/gastrointestinal tract. ## Primary Indications Type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing 5 mg orally once daily. May be taken with or without food. ## Pediatric Dosing Safety and effectiveness in pediatric patients (under 18 years) have not been established. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required. * **Hepatic Impairment:** No dose adjustment required. * **Geriatric:** No dose adjustment required. ## Contraindications * History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). ## Adverse Effects * **Common:** Nasopharyngitis, increased uric acid. * **Serious:** Acute pancreatitis (discontinue if suspected), severe and disabling arthralgia, bullous pemphigoid, hypersensitivity reactions. ## Key Drug Interactions * **Strong P-glycoprotein/CYP3A4 Inducers:** (e.g., rifampin) May decrease linagliptin efficacy. If combined, monitor glycemic control; consider an alternative agent if control is inadequate. * **Insulin/Insulin Secretagogues:** (e.g., sulfonylureas) May increase the risk of hypoglycemia. A lower dose of the secretagogue may be required. ## Monitoring * **HbA1c:** Typically every 3–6 months. * **Pancreatitis:** Monitor for unexplained, severe abdominal pain (with or without vomiting). * **Skin/Joints:** Monitor for new or worsening blistering or severe joint pain. ## Clinical Pearls * Linagliptin is unique among DPP-4 inhibitors as its primary route of elimination is non-renal, making it a preferred choice for patients with significant renal impairment. * Does not cause weight gain. * It is not recommended for use in patients with Type 1 diabetes. * The clinical relevance of the interaction with rifampin is often mitigated by the drug's wide therapeutic index, but monitoring remains appropriate. *** *Disclaimer: This information is for educational purposes and does not constitute medical advice. Always verify current prescribing information, local clinical protocols, and manufacturer labeling before prescribing or administering medication.*